12 Besides glycoprotein Ib, several collagen receptors ... However, the transient incomplete blockade of platelet COX-1 and of glycoprotein IIb/IIIa by some traditional nonsteroidal ...

Binding of anti-glycoprotein IIb/IIIa and anti-glycoprotein Ib monoclonal antibodies to platelets did not differ significantly between the hypertensive patients and controls, but platelet ...

The platelet integrin receptor α IIb β 3 (GPIIb/IIIa) plays a critical role in thrombosis and hemostasis by mediating interactions between platelets and several ligands, primarily fibrinogen.

The participation of platelets in atherogenesis and the subsequent ... on the modulation of soluble ligand binding to integrin-α IIb β 3. Secretion leads to the release of granule components ...

The epitopes targeted by these antibodies usually reside on glycoprotein IIb/IIIa or Ib/V/IX complexes, the major platelet receptors for fibrinogen and von Willebrand factor, respectively.

GP IIb/IIIa antagonists are potent inhibitors of platelet aggregation. A clear understanding of the bleeding risks associated with their use is of particular importance in the cardiac ...

The αIIbβ3 integrin, also known as the platelet fibrinogen receptor or GP IIb-IIIa, has been the focus of an entire class of blood-thinning drugs, called GPIIb-IIIa agonists. The Penn ...

The most common etiology of pseudothrombocytopenia is platelet clumping induced by EDTA, which is the anticoagulant present in the purple tube in which blood is collected for a CBC. This clumping ...

RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, ...

It is recommended that a glycoprotein (GP) IIb/IIIa inhibitor is considered as an adjunct to percutaneous coronary intervention (PCI) for all patients with diabetes undergoing elective PCI, and for ...